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Investigation of polymorphism and solvatomorphism in drug molecules is an im-
portant step in any pre-formulation program from both biopharmaceutical and techno-
logical point of view (1, 2). It is well known that polymorphs are different crystalline
forms of the same compound whereas the inclusion of a solvent in a crystal lattice gives
rise to pseudopolymorphs or solvatomorphs (2). One of the most relevant features among
polymorphic modifications is the difference in their solubility and dissolution rate that
affect their bioavailability (3–5).
In crystal hydrates/solvates, the combination of intermolecular forces (hydrogen
bonding) and crystal packing can produce very strong solvent-solid interactions leading
to completely new properties in the solid state (6, 7). Some stable solvatomorphs require
vigorous conditions for desolvation before melting, while others lose the solvent of crys-
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tallization under much milder conditions and are converted to the amorphous form af-
ter desolvation.
Methotrexate, N-4-[(2,4-diaminopteridin-6-yl-methyl)methylamino]benzoyl-L-glu-
tamic acid, introduced in 1953 as an anti-tumor agent, exerts its effect by inhibiting the
enzyme dihydrofolate reductase (DHFR) and has a broad spectrum clinical activity (8).
It is still the most widely used antifolate drug in spite of frequent development of resis-
tance by various mechanisms.
Literature indicates that not much work has been done on the characterization of
crystal forms of the drug except for one study in which the authors reports that the drug
exists in four different types of solid forms (9). The present study primarily deals with
the screening of possible crystal forms of methotrexate by solvent-mediated transforma-
tion. Given sufficient time, various forms crystallize from a supersaturated solution in
order to establish equilibrium (10).
Sensitive analytical methods such as differential scanning calorimetry, powder
X-ray diffraction, Fourier transform infrared spectroscopy and scanning electron micros-
copy have been used to characterize the various forms (11–17). Above all, much atten-
tion has been paid to utilization of the solution calorimeter, which generates data by dis-
solving a solid compound into a solvent, providing the enthalpy of solution which is a
direct reflection of its lattice energy. As polymorphs/solvatomorphs are solid compounds
that are identical chemically and differ only in crystal structure, solution calorimetry is
the most suitable method for differentiation among the various crystal forms and can be
correlated quantitatively with crystallinity as well as the dissolution profile.
EXPERIMENTAL
Methotrexate samples were provided by GlaxoSmithKline Pharmaceuticals Ltd.,
India. All solvents used in the study were of analytical grade. The buffer used for the
enthalpy of solution and solubility studies was disodium hydrogenphosphate buffer
(pH 7) (18).
Preparation of polymorphs
The various solvates of methotrexate were named according to the order in which
they were prepared in the laboratory. Five forms were obtained in addition to the com-
mercial drug sample. These forms were characterized using DSC, TGA, FTIR, XRPD, ca-
lorimeter and dissolution studies.
Form I was obtained by crystallization in a hot mixture of acetonitrile and water
(50:50). The solution was slowly cooled to room temperature and the crystals obtained
were collected by filtration. These were dried under vacuum to remove traces of the sol-
vent and were finally stored in an airtight container.
Forms II and V were obtained when hot water was added to a saturated solution of
the drug in DMSO and DMF, respectively, at room temperature. The crystals thus ob-
tained were separated by filtration and dried as described for form I.
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Form III was obtained by completely evaporating the solvent under vacuum from a
solution of the drug in methanol, and form IV was directly crystallized from hot water.
The solutions were allowed to stand at room temperature until sufficient crystals were
formed. The procedure described above was followed for drying the crystals.
Characterization of polymorphs
Differential scanning calorimetry (DSC). – DSC thermograms of methotrexate and its
forms were obtained on a Mettler Toledo DSC (Switzerland). The calorimeter was cali-
brated for temperature and heat flow accuracy using pure indium melting (m.p. 156.6 °C
and DH = 25.45 J g–1). The temperature range was from 50–350 °C with a heating rate of
5 °C min–1.
Thermal gravimetric analysis (TGA). – TGA of methotrexate and its forms was per-
formed using a Mettler Toledo 851e TGA/SDTA. Nitrogen was used as purge gas and
the heating rate was kept constant at 5 °C min–1.
X-Ray powder diffraction (XRPD). – Powder diffraction patterns of methotrexate and
its forms were recorded on an X-ray diffractometer (PW 1710 X-ray generator Phillips,
The Netherlands) with Cu as tube anode. Diffractograms were recorded under the fol-
lowing conditions: voltage 35 kV, 20 mA, angular range 5, divergence slit 10, receiving
slit 0.15 mm.
Fourier transform infrared spectrometry (FT-IR). – The FT-IR spectra of methotrexate
and its different forms were obtained on an FT-IR spectrometer, Mode spectrum RXI,
Perkin Elmer (UK) over the range 400–4000 cm–1. Dry KBr (500 mg) was finely ground
in a mortar and the drug sample or its modification (1–2 mg) was subsequently added
and gently mixed in order to avoid trituration of the crystals. A manual press was used
to form pellets.
Enthalpy of solution. – Isoperibol solution calorimeter Model 4300 (Calorimetry Sci-
ence Corporation, USA) was used to determine the enthalpy of solution of the drug and
its different crystal forms. The apparatus consists of a constant temperature bath held at
37 °C (± 0.005 °C) and a heater assembly. The reaction vessel is a 25-mL silvered Dewar
flask. The drug was filled into a 0.9-mL batch adaptor, sealed on both sides with 'O' rings
and cover glasses. The batch adaptor holding the drug was inserted into the Dewar flask
containing the buffer. The glass stirrer was rotated at 100 revolutions min–1 and was al-
lowed to equilibrate for 90 min. The ampoule was shattered using a plunger and the
temperature change was noted. The performance of the system was checked using KCl,
which has a known enthalpy of solution and good agreement (± 0.03 kJ mol–1) was found
with the published value (19).
Scanning electron microscopy. – SEM photographs of each polymorph were taken us-
ing a Jeol JSM-6100 scanning microscope (Japan) after sputtering the selected crystals
with gold.
Dissolution studies. – The drug and other forms were compressed into pellets by ap-
plying a force of 10 tons for 45 s to provide a uniform surface for dissolution. Dissolu-
tion studies were performed using a USP paddle apparatus-12 (20) equipped with a pad-
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dles rotating at 50 rpm in 900 mL of 0.1 mol L–1 HCl pre-equilibrated to 37 ± 0.5 °C. The
samples were withdrawn and analyzed at time intervals of 5, 10, 15, 25, 35, 45, 75, 105
minutes and then every 60 min till the absorbance of the solution became constant. Each
dissolution study was performed on duplicate batches.
RESULTS AND DISSCUSSION
DSC and TG analysis
Initially, the DSC technique (Fig. 1) was used to find out whether a particular form
was a polymorph or solvatomorph (solvates or hydrates). The commercial sample ob-
tained revealed a DSC event peaking at 87.65 °C with a mass loss of 11.11 %. Calcula-
tions showed it to be a trihydrate. Further, DSC and TGA studies showed the desolva-
tion endotherm in the temperature range between 75 and 150 ºC for all forms except for
form III (obtained from methanol). There was no transition corresponding to the melting
endotherm but a broad peak due to decomposition was obtained for all the forms in-
cluding the commercial sample. The DSC thermogram of form I (Fig. 1b) obtained from
acetonitrile and water (50:50) shows an endothermic event (range 76.02 to 110 °C) peak-
ing at 91.82 °C which corresponds to desolvation. The TGA mass loss of 10.94 % was
found to be closer to that calculated (11.5 %) on the basis of 1:1:1 stoichiometry (drug/
acetonitrile/water). Thus, form I is an acetonitrile solvate hydrate. The existence of a mix-
ed solvate with a single desolvation peak has also been reported in the literature (15).
The DSC thermogram of form II obtained from DMSO and water (Fig. 1c) also sho-
wed a dehydration endotherm at 91.72 °C (range 78.32 to 115 °C); the corresponding TGA
experiment revealed a mass loss of 11.22 %. Very low desolvation temperature compared
to the boiling point of DMSO (189 °C) ruled out that it was a mixed solvate. The mass
loss calculation showed it to be a trihydrate (calculated 10.62 %).
Form III obtained from methanol (Fig. 1d) showed no endothermic peak correspon-
ding to desolvation. Moreover, the decomposition peak was broad at 247.20 °C, showing
this form to be partially crystalline. Form IV (Fig. 1e) obtained from water showed mass
loss of 11.26 % at 91.82 °C, which indicates it was a trihydrate. The literature has shown
the existence of trihydrates (9) as well as tetrahydrates (21) of methotrexate. The forma-
tion of a tetrahydrate in the study done by Sutton et al. (21) may be due to the fact that
the glutamate side chain disorder in the molecule imparts disorder to the solvent mole-
cules leading to a variable number of water molecules per unit cell, ranging from 2 to 4
(22).
Form V (Fig. 1f) obtained from DMF and water showed a desolvation endotherm at
120 °C with mass loss of 16.50 % (calculated 16.79 %), showing form V to be a mixed
solvate of DMF and water with the stoichiometry of 1:1:1 (15).
The inspection of DSC plots in all the solvates indicated the presence of a very small
but broad endothermic depression in all the solvates and hydrates between 75–150 °C.
Besides, prior to decomposition there was a small endotherm in all the forms (except
form III) which can be attributed to the solid-solid transition.
248
R. Chadha et al.: Characterization of solvatomorphs of methotrexate using thermoanalytical and other techniques, Acta Pharm. 59
(2009) 245–247.
The binding strength for water and solvents (15, 16, 23) was also calculated for all
the forms (Table I) from the equation:
DHS = [(DHSexp ´ 100)/ DmS%] ´ MS
where DHS (J mol–1) is the heat of vapourization of methotrexate bound solvent, MS is
the molecular mass of the solvent, DHSexp (J g–1) is the enthalpy of desolvation, DmS% is
the percentage mass loss.
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Fig. 1. DSC-TGA plots of: a) commercial methotrexate, b) form I, c) form II, d) form III, e) form IV, f)
form V.
Table I shows that water molecules are not tightly bound in the crystals of methotre-
xate. However, stronger interaction with methotrexate host is noted for DMF and aceto-
nitrile.
The TG results show 16.5 % loss for form V due to desolvation. Forms II, IV and
commercial samples are all trihydrates and show desolvation losses between 11.11 and
11.27 %. Form I, as already explained, is a mixed solvatomorph of acetonitrile and water.
FT-IR spectroscopy
The strong absorption band at 1750–1600 cm–1 assigned to > C=O stretching par-
tially overlaps with the > N-H band which appears in the range 1640–1620 cm–1, mak-
ing > C=O stretch appear as a doublet in the commercial sample (1645.8/1605.0 cm–1) at
1645.7/1603.0 and 1646.3/1602.8 cm–1 for forms II and IV, respectively (Fig. 2). However,
in form I, small kinks appear along with the doublet, which is not very sharp. In form
III, the doublet appeared at 1641.5/1605.7 cm–1. In the case of form V, the number of ab-
sorption bands around this region increased, making this form the different from others.
Besides, there were some observable changes from 3300 to 3400 cm–1 where the band for
–OH and > N-H stretching can be found. The FTIR spectra of the commercial sample,
form II and form IV showed the appearance of a broad peak for NH/OH stretching
around 3300 cm–1 along with small merged peaks around 3000 cm–1 corresponding to
-C-H stretch, while for form III a small doublet at 3332.4/3157.9 cm–1 appeared in this
region. No major change in the peaks from the –OH region appeared for form I. How-
ever, the form V spectrum differed from other samples in having sharp peaks at 3466.0,
3339.1, 3227.3 and 3090.6 cm–1 instead of a broad peak.
XRPD
The XRPD patterns for the commercial trihydrate sample as well as for form II (ob-
tained from DMSO + water) and for form IV (obtained from water) were similar and
could be classified as isomorphic. However, the extent of crystallinity varied among
these forms (Fig. 3). Also, the position of the peak corresponding to 100 % intensity was
different; it was located at 2q of 26.92o in the commercial sample, at 2q of 9.41o in form
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Table I. TGA and DSC data for the commercial sample of methotrexate and its forms
Solvate
Mass loss,
DmS (%)
Desolvation
enthalpy change,
DHSexp (J g–1)
Heat of vaporization of solvent
Bound, DHs
(kJ mol–1)
Pure, DHPS
(kJ mol–1)
Commercial sample (Mt´3H2O) 11.11 127.48 20.67 40.67
Form I (Mt´CH3CN´H2O) 10.94 65.58 35.37 33.22
Form II (Mt´3H2O) 11.27 126.97 20.29 40.67
Form IV (Mt3H2O) 11.27 126.97 20.29 40.677
Form V (Mt´DMF´H2O) 16.55 90.32 49.71 46.89
Mt – methotrexate
II, at 2q of 27.01o in form IV. The deviation in the relative intensity might be accounted
for by some preferred orientation in the sample (15). The XRPD pattern for forms I and
V was definitely different, showing that they crystallized in a distinctly different arran-
gement. In form I, the peak corresponding to 100 % intensity appeared at 2q of 23.3o.
Form III obtained from methanol appeared to be least crystalline among all the forms.
Enthalpy of solution
Polymorphs or solvatomorphs differ in their crystal structures and their individual
heats of solution depend upon the solvent used for enthalpy measurement. The differ-
ence in the heat of solution of different polymorphs/solvatomorphs of a drug is inde-
pendent of the solvent used and will be equal to the difference in lattice energy of the
solids.
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Fig. 2. FTIR Spectra of: a) commercial methotrexate, b) form I, c) form II, d) form III, e) form IV, f)
form V.
Heat of solution of all crystalline forms in the buffer of pH 7 as well as in ethanol
was determined using an isoperibol solution calorimeter and the representative graph
for the enthalpy of solution of form I is given in Fig. 4. All the forms, including the com-
mercial sample, showed endothermic behavior. As expected, the absolute values varied
from 15.20 to 25.78 kJ mol–1 at pH 7 and from 10.33–20.85 kJ mol–1 in ethanol (Table II).
Moreover, the heat of solution for all the forms is less endothermic in ethanol. Form III
exhibited the least endothermic behavior in both solvents. This form is partially crystal-
line, as shown by the XRPD study, characterized by a lack of any long range crystal stru-
cture and is the least ordered phase. A more disordered phase would give rise to low
enthalpy of solution considering the weaker intermolecular interaction in this phase.
Form I obtained from acetonitrile and water exhibited the highest endothermic effect, in-
dicating it was the most ordered form, which is responsible for its higher degree of cry-
stallinity. Heat of solution and dissolution are very well correlated on the basis of Gibb’s
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Fig. 3. XRPD patterns of: a) commercial methotrexate, b) form I, c) form II, d) form III, e) form IV, f)
form V.
free energy and Noyes-Whitney equation (24). This approach has also been used by vari-
ous researchers to investigate the polymorphs of enalapril and terfinadine (16, 25).
SEM
By close visual inspection of the crystal forms, definite differences in morphology
were evident in the drug and its different forms (Fig. 5). The differences were confirmed
by studying the shape and appearance of crystal forms with scanning electron micros-
copy. The differences in the morphology of various forms arose from the difference in
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Fig. 4. Representative graph of the enthalpy of solution of form I determined using the isoperibol
solution calorimeter.
Table II. Molar enthalpy of solution (kJ mol–1)in phosphate buffer (pH 7)/ethanol and solubility
of the commercial sample of methotrexate and its forms in phosphate buffer (pH 7)
Solvate
Molar enthalpy of solution (kJ mol–1) in Solubility in buffer
pH 7 (mg per 100 mL)phosphate buffer (pH 7) ethanol
Commercial sample (Mt´3H2O) 21.69 16.82 567.98
Form I (Mt´CH3CN´H2O) 25.78 20.85 448.12
Form II (Mt´3H2O) 21.96 17.12 571.81
Form III (amorphous) 15.20 10.33 759.16
Form IV (Mt´3H2O) 21.15 16.32 581.24
Form V (Mt´DMF´H2O) 23.48 18.73 538.63
Mt – methotrexate
environmental conditions under which crystals were developed. The commercial sam-
ple displayed a reticulated lattice, consisting of small crystals whereas form II obtained
from DMSO exhibited a lamellar crystal habit, forming thin scales, or plates, resembling
gills or lamellar. Form III had no well defined crystals, showing it to be partially crystal-
line. Form IV had a striated crystal habit, which displayed shallow parallel grooves or
lines along flat crystal faces. Form V displayed an acicular crystal habit, having typically
long and narrow crystal-like pine leaves and possessed a sharp point.
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Fig. 6. Dissolution profile of methotrexate and its various forms in 0.1 mol L–1 HCl at 37 °C (n = 2).
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Fig. 5. Scanning electron micro-
graphs of: a) commercial metho-
trexate, b) form I, c) form II, d)
form III, e) form IV, f) form V.
Dissolution study
The dissolution profiles of the different forms are compared in Fig. 6. The dissolu-
tion rate of the least crystalline form (form III) was significantly higher than any other
form while the dissolution rate of form I was the lowest. These results are also in agree-
ment with the enthalpy of solution, solubility, XRPD and other studies.
CONCLUSIONS
The present study has showed that the nature of the solvent modifies the crystal
form of methotrexate, leading to three solvatomorphs and one partially crystalline form.
The commercial sample was found to be a trihydrate. The acetonitrile solvate was found
to be the most crystalline among all forms while the form obtained from methanol was
found to be partially crystalline. The success of the results depended on the use of solu-
tion calorimetry by determining the enthalpy of solution of all forms. The forms were
found to be endothermic but the magnitude decreased in the following order: form I >
form V > form II  form IV  commercial sample > form III. The solubility and dissolu-
tion study followed the same trend, indicating that form III was the least endothermic,
most soluble and had the highest rate of dissolution.
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S A @ E T A K
Karakterizacija solvatomorfa metotreksata pomo}u
termoanaliti~kih i drugih metoda
RENU CHADHA, POONAM ARORA, RUPINDER KAUR, ANUPAM SAINI, MADAN LAL SINGLA i DHARAMVIR SINGH JAIN
U radu je provedena identifikacija i karakterizacija pet razli~itih formi metotreksata
dobivenih kristalizacijom iz razli~itih otapala. Desolvatacijska izoterma u DSC popra}e-
na gubitkom mase u TGA za forme I, II, IV i V ukazuje da su te forme solvati s aceto-
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nitrilom: hidrat (forma I), trihidrat (forma II i IV) i solvat s dimetilformamidom (forma
V). Me|utim, desolvatacijski pik je odsutan u formi III (dobivenoj iz metanola) {to uka-
zuje na odsutnost otapala u kristalnoj formi. Ta forma je parcijalno kristalna i pokazuje
odgovaraju}i XRPD uzorak. Energija kristalne }elije je za razli~ite forme razli~ita, {to ima
za posljedicu razli~ite entalpije otapanja te omogu}ava primjenu kalorimetrije otopine
za diferencijaciju formi. Topljivost je korelirana s entalpijom otopine i kristalini~nosti svih
formi. Najmanje endotermna forma (forma III) je najbolje topljiva.
Klju~ne rije~i: solvatomorf, pseudopolimorf, metotreksat, entalija otopine, kalorimetrija otopine, de-
solvatacija, topljivost
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